Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes
Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...
Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages
Canaccord Genuity analyst Edward Nash has maintained their bullish stance on CORT stock, giving a Buy rating on December 6.Pick the best ...
Corcept Therapeutics Fall 3.5 After ALS Drug Fails Trial
Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.
FiercePharma2d
Corcept shows how excess cortisol might be pulling the strings in Cushing syndrome awareness campaign
Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics ...
FierceBiotech3d
Corcept's cortisol modulator fails to slow ALS decline, linked to 'gastrointestinal upset' at onset
Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...
Business Insider2d
Corcept Therapeutics (CORT) Receives a Buy from Truist Financial
Lee covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Argenx Se, and Wave Life Sciences. Currently, the analyst consensus on Corcept Therapeutics is a Strong Buy with an ...
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study
Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Consensus Target Price from Brokerages
Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) have been assigned an average rating of “Buy” ...
devdiscourse2d
Health Sector Faces Challenges Amid Drug Trials, Legislation, and Climate Concerns
Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...